Radiation Pharma is a nuclear drug developer seeking to own the full value chain of radioligand production, research, development and commercialization in order to bring more clinical benefits to patients. The core platform aims to address two core issues in radiopharmaceuticals today: 1. the ability to produce high-quality and quantitative radioisotopes to meet future needs, and 2. an innovative translational and biological research platform for future radiopharmaceutical treatments. It has recently completed nearly 250 million yuan in Series A financing, led by Sequoia China, and joined by Yinglian Health Fund, Jiachen Capital, Chende Capital and Kunlun Capital. Funds from this round will be used to advance the development of its radiopharmaceutical oncology product pipeline and radioactive medical isotope production platform.
This article is reproduced from: https://www.itjuzi.com/investevent/13244096
This site is for inclusion only, and the copyright belongs to the original author.